MedTrace Logo

The Role of Immune Semaphorins in NAFLD

NCT04573543 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2023-08-30

No results posted yet for this study

Summary

To goal is to identify semaphorins that are associated with NAFLD and to investigate their relationship with variable degrees of steatosis and fibrosis.

Conditions

  • Non-Alcoholic Fatty Liver Disease
  • Immune Response
  • Biomarkers
  • Liver Fibrosis
  • Non Alcoholic Steatohepatitis

Interventions

DIAGNOSTIC_TEST

Evaluation of the degree of fibrosis and steatosis

The degree of steatosis will be estimated using the controlled attenuation parameter (CAP), a method for grading steatosis by measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of fibrosis.

DIAGNOSTIC_TEST

Screening for the components of metabolic syndrome

Anthropometric measures including body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), and waist height ratio (WHtR) will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: bilirubin, AST, ALT, GGT, ALP, albumins, WBC, neutrophil-to-lymphocyte ratio, hemoglobin, platelet count, fasting glucose, triglycerides, cholesterol, HDL and LDL. Non-invasive scores of steatosis/fibrosis will be calculated (APRI, FIB4, NAFLD score). Patients will be screened for the components of metabolic syndrome.

DIAGNOSTIC_TEST

Measurement of serum semaphorin concentrations

Semaphorin concentration will be measured in patient sera by ELISA.

DIAGNOSTIC_TEST

Identification of semaphorin gene polymorphisms

Semaphorin genes will be sequenced to identify semaphorin gene polymorphisms associated with NAFLD.

Sponsors & Collaborators

  • Croatian Science Foundation

    collaborator OTHER_GOV

  • University Hospital for Infectious Diseases, Croatia

    lead OTHER

Principal Investigators

  • Neven Papic, MD, PhD · University Hospital for Infectious Diseases Zagreb

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-09-01
Completion
2022-03-01

Countries

  • Croatia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04573543 on ClinicalTrials.gov